Skip to main content
Signal8

PaxMedica, Inc. Common Stock (PXMD)

Sector: Biotechnology

Industry: Biotechnology

PaxMedica, Inc. Common Stock logo

PaxMedica, Inc. Common Stock

OTC:PXMDHealthcare
$0.0005
CLOSED
Mkt Cap$63K
EV-
Float10.69M
O/S126.26M
VOL759 sh
$ Vol$0
RVOL0.14×
Inst Own-
SI<0.1%
Net Cash/Sh-
EarningsDec 2 · in 2w
Dilution
PaxMedica, Inc. Common Stock logoOTC:PXMDClosed$0.0005
Historical Data
DateOpenHighLowCloseVolume
Nov 16, 20260.00050.00050.00050.0005759
Nov 11, 20260.00050.00070.00050.0007569
Nov 6, 20260.00050.00070.00050.000720,965
Oct 23, 20260.00070.00070.00070.00073,500
Oct 22, 20260.00050.00050.00050.00051,577
Oct 14, 20260.00050.00050.00050.0005257
Oct 8, 20260.00070.00070.00070.0007180
Oct 7, 20260.00050.00050.00050.0005117
Oct 6, 20260.00070.00070.00070.0007451
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
0.0%
Institutional
(0)
0.0%
Insiderⓘ
(0)
0.0%
5%+ Owners
(0)
100.0%
Unattributed (incl. retail)ⓘ
Unattributed (incl. retail)100.0%
Sources: O/S: 126.3M · checked 8 Oct 2026 · market-data provider
About

PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms.

The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and human African trypanosomiasis. Furthermore, PaxMedica is also developing PAX-102, an intranasal version of suramin, intended for various neurological applications.

The company, which was incorporated in 2018 and has its headquarters in Tarrytown, New York, previously operated as Purinix Pharmaceuticals LLC before rebranding to PaxMedica, Inc. in April 2020.

It functions as a subsidiary of Tardimed Sciences LLC.

Key Metrics
Market Cap$63,132
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership-

No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryUSUS
IPO DateAug 26, 2022
Shares Outstanding126.26M
Authorized Shares
Float10.69M
52-Week Range
$0.0000$0.0080
$0.0005(6th percentile)
Volume
Average Daily Volume5.47K
759 today vs 5.47K avg(-86%)

30d Avg

5.47K

60d Avg

2.17K

90d Avg

3.41K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

PaxMedica, Inc. Common Stock (OTC: PXMD) traded at $0.0005 on Nov 16, 2026. 52-week range: $0.0000 to $0.0080. The company is in the Healthcare sector (Biotechnology).